Real-World data reveals palbociclib use in japanese breast cancer patients
NCT ID NCT05153187
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study analyzed medical records of 1,170 advanced breast cancer patients in Japan to see how they used the drug palbociclib (Ibrance). Researchers looked at blood test frequency and how long patients stayed on treatment. The goal was to describe real-world treatment patterns, not to test a new therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- palbociclib (Ibrance)
- What this could lead to
- If successful, this could help doctors better understand how palbociclib is used in real-world settings, potentially improving treatment guidelines for advanced breast cancer in Japan.
- What could go wrong
- This is an observational study that only describes existing data, not testing a new treatment. It cannot prove what works best, and results may not apply outside Japan.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer Japan
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a Two-Step drug combo outsmart advanced HER2-Positive breast cancer?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple